ByTrending Posts
How are NVIDIA & Taiwan’s 22 Medical Centers…
May 18, 2025 In a landmark initiative signaling the rapid digital transformation of Asia’s healthcare ecosystem, several leading…
BioNTech to Launch £1 Billion AI-Powered R&D Hub…
Investment to Accelerate AI Innovation in Oncology, Personalized Medicine, and Drug Development May 21, 2025 Establishing an AI-Centric…
Regeneron, Sanofi & Viz.ai: How Are These Industry…
May 20, 2025 In a bold strategic alliance, Regeneron and Sanofi have teamed up with AI healthcare innovator…
How RevolKa’s $1.7M Series A Extension Fuels AI-Driven…
Sendai, Japan – May 20, 2025 RevolKa Ltd., a fast-growing biotechnology company leveraging AI for protein engineering, has…
Foxconn and NVIDIA: How Can AI-Driven Robotics Address…
May 18, 2025 In response to the World Health Organization’s projection of a 4.5 million nurse shortage by…
Is Quantum AI the Future of RNA Drug…
Key Highlights: INDIANAPOLIS, IN & SAN DIEGO, CA – In a major signal of the industry’s growing confidence…
Johnson & Johnson MedTech and Qure.ai Partner to…
May 10, 2025 – IndiaJohnson & Johnson MedTech has announced a strategic collaboration with healthcare AI innovator Qure.ai…
Can Eli Lilly and Purdue University reshape pharmaceutical…
The initiative will focus on applying artificial intelligence, robotics, and data science to improve every stage of the…
AI-driven ALS therapy: How Eli Lilly is expanding…
Key highlights AI-powered discovery enters clinical stageEli Lilly and Company has entered into a licensing agreement with Alchemab…
Trending Posts
Latest Stories
Did AstraZeneca’s 2025 Deals Lay the Groundwork for Transformative Growth Across Oncology, Immunology, and Rare Diseases in 2026?
In 2025, AstraZeneca executed a series of strategic collaborations, partnerships, and selective acquisitions designed to…
Can AstraZeneca’s 2025 Execution Propel It to Leadership Across Oncology, CVRM, and Immunology in 2026?
AstraZeneca concluded 2025 as a company demonstrating resilient performance, focused execution, and continued innovation across…
How Did Sanofi’s 2025 Deals Shape Its Strategy and What Do They Mean for the Future?
In 2025, Sanofi pursued a series of strategic collaborations, acquisitions, and licensing agreements aimed at…
What Lessons from Sanofi’s 2025 Execution Signal Its Future in Oncology, Immunology, and Vaccines?
Sanofi concluded 2025 with a combination of solid portfolio performance, strategic execution, and continued innovation…
Gallery
